RVL Pharmaceuticals PLC
NASDAQ:RVLP
RVL Pharmaceuticals PLC
NASDAQ:RVLP
Price:
0.0024 USD
14.29%
Updated:
May 7, 2024
RVL Pharmaceuticals PLC
Revenue
|
RVL Pharmaceuticals PLC
Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
RVL Pharmaceuticals PLC
NASDAQ:RVLP
|
Revenue
$49.7m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
RVL Pharmaceuticals PLC
Revenue Breakdown
Breakdown by Geography
RVL Pharmaceuticals PLC
RVL Pharmaceuticals PLC
Not Available
Breakdown by Segments
RVL Pharmaceuticals PLC
RVL Pharmaceuticals PLC
|
Total Revenue:
49.7m
USD
|
|
Upneeq:
34.2m
USD
|
|
Royalty And Licensing Revenue:
15.5m
USD
|
See Also
What is RVL Pharmaceuticals PLC's Revenue?
Revenue
49.7m
USD
49.7m
USD
Based on the financial report for Dec 31, 2022, RVL Pharmaceuticals PLC's Revenue amounts to 49.7m USD.
What is RVL Pharmaceuticals PLC's Revenue growth rate?
Revenue CAGR 5Y
-27%
-27%
Over the last year, the Revenue growth was 184%. The average annual Revenue growth rates for RVL Pharmaceuticals PLC have been -41% over the past three years , -27% over the past five years .
You don't have any saved screeners yet
